PTGS2 and pachyonychia congenita: More recently, apricoxib, a novel COX-2 inhibitor in phase II clinical trials, was found to significantly enhances the efficacy of gemcitabine/erlotinib in PC and promoting vascular normalization and reversed EMT (223).